Navigation Links
Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis

Treatment with Copaxone Plus Minocycline Showed Substantial Reduction of Disease Activity in Patients with Active Relapsing-Remitting Multiple Sclerosis

Combination Treatment With Antibiotic Further Reduced Brain Lesions and Was Well Tolerated

KANSAS CITY, Mo, May 4, 2007 - New data from a randomized, double-blind study showed that a combination of Copaxone (glatiramer acetate injection) along with the oral antibiotic minocycline reduced T1 Gadolinium (Gd)-enhancing lesions of the brain by 63 percent (p=0.08) in patients with active relapsing-remitting multiple sclerosis (RRMS), as measured by magnetic resonance imaging (MRI), compared to those receiving Copaxone alone. Additionally, the nine-month study demonstrated that treatment with Copaxone in combination with minocycline reduced the number of new T2 lesions in patients by 65 percent (p=0.06). These results trended toward but did not reach statistical significance.

These data were presented at the 59th Annual Meeting of the American Academy of Neurology (AAN) in Boston, MA, April 28 - May 5, 2007.

"The results of this study indicated that further exploration of this combination is warranted, as the established effect of COPAXONE(r) on disease activity may be boosted when used in combination with minocycline for the treatment of active relapsing-remitting patients," said Luanne Metz, M.D., professor at the Department of Clinical Neuroscience of the University of Calgary, and principal investigator. "In these patients, the combination was safe and well tolerated," she added.

Minocycline is a broad-spectrum antibiotic, which is used to treat pneumonia, acne, and infections of the skin, genital and urinary systems, and the central nervous system. In a small proof-of-concept trial of 10 RRMS patients, minocycline demonstrated an 84 percent relative reduction in mean total Gd-enhancing lesions and was well tolerated, and data p
'"/>




Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Point of Care Strep Tests Speed Treatment, Lower Costs
2. Rapid HIV Testing Increases Possibility of Treatment
3. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
4. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
5. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
6. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
7. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
8. TMC125 Showed Significant Virologic Response at Week 24 in Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3 Trials
9. New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
10. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
11. Peer Reviewed Journal Article Indicates Repros Proellex Exhibits Potential for New Approach to the Treatment and Prevention of Breast Cancer

Post Your Comments:
(Date:11/23/2009)...wire-FirstCall/--Pharmasset,Inc.(Nasdaq: VRUS )ann...nerRoche(SWX:ROG.VX;RO.S,OTCQX:RHHBY),willcontinue...gphase2btrialofRG7128,afirst-in-classnucleosideana...titisCvirus(HCV)infection.Thedecisionwasreachedaft...mittee(DMC)ofallavailablesafetydatafromthefirstcoh...
(Date:11/23/2009)....23/PRNewswire-FirstCall/--CeptionTherapeutics,Inc...on,Inc.(Nasdaq: CEPH )todayannouncedresultsfromaPh...satreatmentforpediatriceosinophilicesophagitis(EoE...primaryendpointsofchangesinesophagealeosinophillev...hatpatientstreatedwithCINQUILshowedastatisticallys...
(Date:11/20/2009)...wswire-FirstCall/ -- Escalon Medical Corp. (Nasdaq...l first quarter ended September 30, 2009. ,, ...nue decreased approximately $234,000, or 2.7%, to ...tember 30, 2009 as compared to the same period las... net revenue of $8,434,000 compared with $8,669,00...
Breaking Medicine Technology:Pharmasset Announces the Continued Enrollment of the Phase 2b Clinical Trial of RG7128 for the Treatment of Hepatitis C 2Pharmasset Announces the Continued Enrollment of the Phase 2b Clinical Trial of RG7128 for the Treatment of Hepatitis C 3Pharmasset Announces the Continued Enrollment of the Phase 2b Clinical Trial of RG7128 for the Treatment of Hepatitis C 4Ception Therapeutics and Cephalon Provide Initial Results of a Phase IIb/III Study of CINQUIL in Pediatric Eosinophilic Esophagitis 2Ception Therapeutics and Cephalon Provide Initial Results of a Phase IIb/III Study of CINQUIL in Pediatric Eosinophilic Esophagitis 3Ception Therapeutics and Cephalon Provide Initial Results of a Phase IIb/III Study of CINQUIL in Pediatric Eosinophilic Esophagitis 4Escalon(R) Reports First Quarter Fiscal 2010 Results 2Escalon(R) Reports First Quarter Fiscal 2010 Results 3Escalon(R) Reports First Quarter Fiscal 2010 Results 4Escalon(R) Reports First Quarter Fiscal 2010 Results 5Escalon(R) Reports First Quarter Fiscal 2010 Results 6Escalon(R) Reports First Quarter Fiscal 2010 Results 7Caraco Pharmaceutical Laboratories Ltd Announces Filing of Purported Class Action Lawsuits 52622 1Caraco Pharmaceutical Laboratories Ltd Announces Filing of Purported Class Action Lawsuits 52622 2Carnegie Mellon team makes sequestration recommendations 9339 1Carnegie Mellon team makes sequestration recommendations 9339 2Renaissance Grants 243 000 to the Florida Dental Association to Present Oral Health Workshops for the Vulnerable Elderly 52615 1Renaissance Grants 243 000 to the Florida Dental Association to Present Oral Health Workshops for the Vulnerable Elderly 52615 2Renaissance Grants 243 000 to the Florida Dental Association to Present Oral Health Workshops for the Vulnerable Elderly 52615 3
...da and Scripps Research in La ...and LA JOLLA, Calif., May 14 /PRNewswire-,FirstCal... ), a,biopharmaceutical company focused on oncolog...t biomedical research organization, today announce...asses of protein kinase,inhibitors for the treatme...
...ncorporated (Nasdaq: KOSN ) today announced that ...e company,s lead Hsp90 inhibitor, from a Phase,2 t...with HER2-positive,metastatic breast cancer, at th...linical Oncology (ASCO), being held at McCormick P...bstract 1027, titled, "Phase 2 trial of the Hsp90 ...
Other Medicine Technology:Poniard Pharmaceuticals Licenses Kinase Inhibitors From The Scripps Research Institute 2Poniard Pharmaceuticals Licenses Kinase Inhibitors From The Scripps Research Institute 3Poniard Pharmaceuticals Licenses Kinase Inhibitors From The Scripps Research Institute 4Kosan Announces Data Presentations at ASCO 2008 Annual Meeting 2Kosan Announces Data Presentations at ASCO 2008 Annual Meeting 3
(Date:11/23/2009)...,, SANDIEGO,Nov.23/PRNewswire/--VictoryPharma,I...74;DoseCard,afurtherextensionofVictory,sNAPRELANfr...tswhorequirerelieffrommildtomoderatepainandinflamm...initisandbursitis.Itisalsodesignedforpatientssuffe...ereceivingothertherapiesandneedadditionalanti-infl...
(Date:11/23/2009)...pert says findings support link between mental and...althDay News) -- Being depressed might take as man... suggests. , However, a combination of depressi...than just depression. , Researchers came to the... survey of more than 60,000 people. During the fou...
(Date:11/23/2009)...most 20 percent get infected within one year of st...MONDAY, Nov. 23 (HealthDay News) -- As many as one...ansmitted disease (STD), many infected soon after ...ort shows. , "The high burden of STDs among tee...d study author Dr. Sami L. Gottlieb, from the divi...
(Date:11/23/2009)...Women who store fat on their waist in middle age a...hen they get older, reveals a new study from the S...blished in the scientific journal Neurology . , ...s at greater risk of dying prematurely due to a he...ior lecturer at the Sahlgrenska Academy. "If they ...
(Date:11/23/2009)...MAYWOOD, Il. -- A Loyola University Health System ...ics is morbidly obese -- approximately 100 pounds ...62.4 percent of U.S. adults with Type 2 diabetes a...ng African American adults with Type 2 diabetes, 1...besity among people with diabetes is increasing at...
Breaking Medicine News(10 mins):Health News:Victory Pharma, Inc. Announces Launch of NAPRELAN(R) Dose Card 2Health News:Depression May Up Death Risk to That of Smoking 2Health News:One in Four Teen Girls Have STDs 2Health News:One in Four Teen Girls Have STDs 3Health News:Diabetics show alarming increase in morbid obesity 2
... A Lifeclinic LC300 automated blood pressure ...me talk show, The Doctors. The series airs each we...m a panel of four practicing medical professionals... on the new CBS daytime talk show, The Doctors. Th...
...ded and gsi interactive Named as Digital Marketing...TSBURGH, Pa., Dec. 16 GSI Commerce Inc. (Nasdaq: ...tichannel solutions, today announced a multiyear e...lements. Under the agreement, which runs through ...
... reach immune cells in just 4 hours , , TU...male-to-female transmission of HIV -- in which the...reach immune cells in just four hours -- has been ...tercourse, because the large HIV virus couldn,t pe...
...., Dec. 16 Third Brigade,( http://www.thirdbrigad...ion,for dynamic datacenters, today announced that ...eployed Third Brigade Deep Security for increased,...l,data resulting from nearly three quarters of a m...
...ty letter scores increased similarly in all treatm...swire-FirstCall/ - QLT Inc. (NASDAQ: QLTI ; TSX:...terim analysis for the Phase II RADICAL study (Red... study comparing reduced-fluence Visudyne(R)-Lucen...
... CeloNova BioSciences, Inc., announced,today that ...e U.S. Food and,Drug Administration (FDA) for Embo...icated for the treatment of hypervascularized tumo...l sales of,Embozene(TM) Microspheres will begin im...
Other Medicine News:Health News:Benefits of a Lifeclinic LC300 Automated Blood Pressure Monitor Recently Featured on Daytime Medical Talk Show 2Health News:GSI Commerce and GNC Corporation Extend E-Commerce Agreement Through 2017 2Health News:GSI Commerce and GNC Corporation Extend E-Commerce Agreement Through 2017 3Health News:HIV Can Penetrate a Woman's Healthy Genital Skin 2Health News:Beth Israel Deaconess Medical Center Maintains Healthy IT Servers With Third Brigade 2Health News:QLT announces interim results of radical study evaluating Visudyne combination therapy 2Health News:QLT announces interim results of radical study evaluating Visudyne combination therapy 3Health News:QLT announces interim results of radical study evaluating Visudyne combination therapy 4Health News:QLT announces interim results of radical study evaluating Visudyne combination therapy 5Health News:CeloNova BioSciences Receives FDA Market Approval for Embozene(TM) Color-Advanced Microspheres Embolization Platform 2Health News:CeloNova BioSciences Receives FDA Market Approval for Embozene(TM) Color-Advanced Microspheres Embolization Platform 3Health News:CeloNova BioSciences Receives FDA Market Approval for Embozene(TM) Color-Advanced Microspheres Embolization Platform 4
...ratories is a national reference laboratory and a ... and development. ARUP offers an extensive test me...linical and anatomic pathology. Owned by the Unive...more than half of the nation's university teaching...
...ratories is a national reference laboratory and a ... and development. ARUP offers an extensive test me...linical and anatomic pathology. Owned by the Unive...more than half of the nation's university teaching...
...ratories is a national reference laboratory and a ... and development. ARUP offers an extensive test me...linical and anatomic pathology. Owned by the Unive...more than half of the nation's university teaching...
...ratories is a national reference laboratory and a ... and development. ARUP offers an extensive test me...linical and anatomic pathology. Owned by the Unive...more than half of the nation's university teaching...
Medicine Products: